The bill adds a new, standalone registration under the Controlled Substances Act that allows physicians to directly administer Schedule I investigational drugs to patients who meet the Federal Right to Try criteria. It ties eligibility to the definitions in section 561B of the FD&C Act and places implementation, registration decisions, and rulemaking authority with the Attorney General.
This change creates an administrative route for access to experimental Schedule I therapies outside clinical trials and directs the Attorney General to establish operational rules and diversion controls. The shift matters because it alters who approves access, how quickly physicians can be authorized, and how enforcement and recordkeeping will be managed for substances that are currently tightly restricted.
At a Glance
What It Does
Requires physicians to apply to the Attorney General for a special registration to administer Schedule I investigational drugs to Right‑to‑Try patients and lists what must be in the application (manufacturer verification, supply agreement and administration guidance, site description, credentials, and state‑law compliance). The Attorney General must register or issue a show‑cause order within set windows, allow electronic filing, cap possession to amounts in the application (with a supplemental notification process), permit a single registration for multiple nearby sites under one institution, and complete accelerated rulemaking followed by a final rule.
Who It Affects
Directly affects physicians who want to administer Schedule I investigational drugs, sponsors/manufacturers that must verify eligibility and agree to supply and provide administration guidance, the Department of Justice/DEA (for registration, oversight, and rulemaking), hospitals and institutions that host treatments, and Right‑to‑Try patients seeking access to Schedule I therapies.
Why It Matters
It creates a federally administered access pathway for drugs currently unavailable outside trials, reallocates administrative burden to the Attorney General/DEA, and forces manufacturers and clinicians to establish supply and security practices for Schedule I substances — all of which raise diversion‑control, legal, and clinical‑trial implications.
More articles like this one.
A weekly email with all the latest developments on this topic.
What This Bill Actually Does
The bill inserts a new subsection into the Controlled Substances Act that authorizes the Attorney General to register individual physicians to give certain Schedule I investigational drugs to patients who qualify under the Federal Right to Try statute (FD&C Act section 561B). Rather than treating such access as ad hoc, the statute sets out an application-driven regime: a physician must show they already hold a valid registration for controlled substances in schedules II through V, confirm state law allows the treatment, and provide proof that the manufacturer or sponsor has verified the drug as eligible and agreed to supply it along with instructions for use.
Applications must include practical details designed to limit diversion and ensure clinician competence: the proposed amount of drug, the storage and administration sites, evidence of relevant training or credentials, and a commitment to follow the manufacturer's guidance in treating eligible patients. The Attorney General (acting through DEA processes) has a short statutory window to register the applicant or initiate an adverse proceeding.
If a physician needs more drug than initially requested, the statute provides a supplemental notification route that becomes effective automatically if the agency does not act within a specified period.Operational controls get specific attention. The law permits one registration to cover multiple treatment locations provided they are under the same institutional control and located in the same city or county, limiting paperwork for systemized providers.
It also forces the Attorney General to issue an interim final rule rapidly (on an abbreviated process) covering delivery, storage, recordkeeping, and the mechanics of suspension or revocation, followed by a conventional final rule within two years. The net effect is a federal framework that converts Right‑to‑Try access for Schedule I investigational drugs into a regulated, administratively supervised program with both access and security components.
The Five Things You Need to Know
A physician must already hold a valid registration to dispense or administer controlled substances in schedules II–V to be eligible to apply for the new Schedule I Right‑to‑Try registration.
The Attorney General must either register an applicant or serve an order to show cause within 45 days after receiving a complete application.
If a physician needs additional quantities beyond the application, a supplemental notification to the Attorney General is deemed approved if the agency does not act within 30 days.
The manufacturer or sponsor must provide documentation verifying the drug is an eligible investigational drug and agree to supply it and provide administration guidance to the treating physician.
The Attorney General must issue an interim final rule to implement these provisions within 240 days, and a final rule consistent with standard APA procedures no later than two years after the interim rule.
Section-by-Section Breakdown
Every bill we cover gets an analysis of its key sections.
Adopts Right‑to‑Try statutory definitions
The provision imports the terms 'eligible investigational drug' and 'eligible patient' directly from section 561B of the FD&C Act. That linkage means eligibility for the special registration is governed by the same patient‑qualifying criteria and drug‑status assessments used by the Federal Right to Try statute, rather than by an independent DEA standard. Practically, manufacturers’ determinations under FD&C section 561B will control whether the drug can flow through this registration process.
Attorney General must register physicians to administer Schedule I investigational drugs
The Attorney General (operationally the DEA) gains explicit authority to issue registrations permitting physicians to directly administer Schedule I investigational drugs to Right‑to‑Try patients. This is a targeted expansion of 21 U.S.C. 823 registration types and places responsibility for vetting, approving, and later suspending or revoking those registrations with DOJ/DEA rather than FDA or state licensing alone.
Detailed application requirements to reduce diversion risk
Applicants must provide evidence of an existing schedule II–V registration, state‑law clearance, training/credentials, a description of storage and administration sites, the quantity requested, and manufacturer documentation and agreement to supply and provide administration guidance. The bill also allows the Attorney General to require additional information 'necessary to prevent diversion,' which gives the agency discretion to expand documentation requirements during rulemaking or individual reviews.
Short statutory action windows and electronic submissions
Once a complete application is filed, the Attorney General has 45 days to grant registration or issue an order to show cause under the existing adverse‑action procedures. The statute requires an electronic filing option, streamlining intake and creating a predictable cadence for agency action — and for clinicians seeking swift patient access.
Possession caps, supplemental approvals, and multi‑site registrations
A registrant may possess only the amounts specified in the application unless they file a supplemental notification for more; that supplemental is automatically effective after 30 days unless blocked by an order to show cause. The bill also permits a single registration to cover multiple treatment locations provided those sites are under the same institutional control and located within the same city or county, reducing duplication for health systems that plan to offer these therapies at multiple nearby sites.
Accelerated interim rule followed by a conventional final rule
The Attorney General must issue an interim final rule within 240 days (bypassing normal notice-and-comment procedures) to set out delivery, storage, security, records, and renewal/suspension processes, and must issue a final rule under standard Administrative Procedure Act procedures within two years. Those deadlines force quick regulatory action to operationalize the new registration program but expose the interim regulation to potential legal and stakeholder scrutiny.
This bill is one of many.
Codify tracks hundreds of bills on Healthcare across all five countries.
Explore Healthcare in Codify Search →Who Benefits and Who Bears the Cost
Every bill creates winners and losers. Here's who stands to gain and who bears the cost.
Who Benefits
- Right‑to‑Try eligible patients with life‑threatening conditions: They gain a clearer, federal pathway to receive Schedule I investigational drugs outside clinical trials when manufacturers and physicians participate.
- Physicians already registered for schedules II–V: Clinicians with existing controlled‑substance registrations and relevant training can obtain a targeted registration to directly administer experimental Schedule I therapies without creating a bespoke state‑by‑state workaround.
- Health systems and multi‑site providers: The single‑registration option for sites under common institutional control reduces administrative duplication for hospitals or clinics that plan systemwide programs.
- Manufacturers/sponsors that want expanded access programs: Sponsors can provide investigational Schedule I drugs directly to patients under Right to Try with an explicit federal channel for distribution and administration, which may complement compassionate‑use strategies.
Who Bears the Cost
- Department of Justice/DEA: The agency must intake electronic applications, adjudicate registrations within tight windows, issue an interim rule on an accelerated timeline, and enforce diversion controls — all without new funding in the statute.
- Treating physicians and clinics: Clinicians must assemble documentation, maintain records, secure storage, and implement sponsor guidance, creating administrative and compliance burdens and potential professional‑liability exposure.
- Manufacturers/sponsors: Companies must verify eligibility, agree to supply drugs outside trials, and provide administration guidance — adding logistical, regulatory, and potential legal obligations.
- State regulators and law enforcement: States must coordinate licensure and enforcement boundaries since applicants must confirm state‑law permissibility; local agencies may face increased diversion risk and enforcement demands.
Key Issues
The Core Tension
The central dilemma is access versus control: the bill expands patient access to investigational Schedule I therapies under Right to Try but does so without weakening the obligation to prevent diversion and misuse. Speedy authorization and automatic supplemental approvals improve patient access but heighten enforcement and safety risks; stricter anti‑diversion requirements protect public health but can slow or block access for the patients the statute intends to help.
The bill attempts to thread a narrow needle: it expands access to experimental Schedule I therapies while insisting on diversion controls and rapid federal oversight. That dual objective creates a series of practical tensions.
The statute gives the Attorney General authority to require additional anti‑diversion information and to promulgate security and recordkeeping rules, but it also forces abbreviated federal rulemaking and tight statutory windows for registration and supplemental approvals. Those schedule‑driven timelines and the 'deemed approved' mechanic for supplemental notifications create risk if the agency is under‑resourced or faces legal challenges to the interim rule.
Other unresolved implementation questions include how the Attorney General will determine sufficiency of manufacturer 'guidance' (and whether guidance can be standardized), how distribution logistics for Schedule I substances will work in practice without creating new diversion points, how the program will interact with ongoing clinical trials and informed‑consent regimes, and whether states can restrict or block access even when federal registration is granted. The statute does not allocate funds for DEA staffing, does not add explicit civil‑liability or indemnity rules for manufacturers or physicians, and gives broad agency discretion to set additional anti‑diversion requirements — all of which could affect how the rule and program operate in the real world.
Try it yourself.
Ask a question in plain English, or pick a topic below. Results in seconds.